Anissa Abi-Dargham Selected Research

McN 5652

12/2003	Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652.
12/2002	Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anissa Abi-Dargham Research Topics

Disease

69	Schizophrenia (Dementia Praecox) 01/2022 - 05/2002
9	Psychotic Disorders (Schizoaffective Disorder) 01/2022 - 06/2002
6	Alcoholism (Alcohol Abuse) 01/2018 - 11/2005
5	Cognitive Dysfunction 01/2015 - 10/2003
4	Schizotypal Personality Disorder 09/2020 - 05/2004
4	Mental Disorders (Mental Disorder) 01/2020 - 11/2003
3	Hallucinations (Hallucination) 12/2019 - 01/2011
3	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 11/2011 - 12/2003
3	Social Phobia 01/2009 - 12/2002
2	Cocaine-Related Disorders (Cocaine Addiction) 11/2020 - 06/2009
2	Major Depressive Disorder (Major Depressive Disorders) 01/2020 - 10/2018
2	Heroin Dependence (Heroin Abuse) 07/2014 - 04/2012
2	Substance-Related Disorders (Drug Abuse) 07/2012 - 12/2006
1	Cerebral Cortical Thinning 01/2020
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020
1	Opioid-Related Disorders (Opiate Addiction) 01/2019
1	Anhedonia 10/2018
1	Hypotension (Low Blood Pressure) 01/2015
1	Tachycardia (Tachyarrhythmias) 01/2015
1	Dizziness (Lightheadedness) 01/2015
1	Marijuana Abuse (Cannabis Abuse) 07/2014
1	Bulimia Nervosa 07/2012
1	Autism Spectrum Disorder 12/2011
1	Asperger Syndrome (Asperger's Syndrome) 12/2011
1	Mood Disorders (Mood Disorder) 12/2006

Drug/Important Bio-Agent (IBA)

57	Dopamine (Intropin)FDA LinkGeneric 01/2022 - 09/2003
16	Antipsychotic Agents (Antipsychotics)IBA 01/2022 - 06/2002
13	Pharmaceutical PreparationsIBA 01/2022 - 05/2002
9	Serotonin (5 Hydroxytryptamine)IBA 01/2022 - 12/2002
9	Amphetamine (Amfetamine)FDA LinkGeneric 01/2021 - 03/2004
8	Glutamic Acid (Glutamate)FDA Link 01/2019 - 11/2003
4	Dopamine D1 Receptors (Dopamine D1 Receptor)IBA 01/2021 - 05/2002
4	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 01/2020 - 06/2005
4	gamma-Aminobutyric Acid (GABA)IBA 11/2015 - 01/2010
3	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2022 - 12/2008
3	Cholinergic Agents (Cholinergics)IBA 01/2022 - 12/2006
3	Protons (Proton)IBA 01/2019 - 05/2012
3	dihydrexidineIBA 01/2016 - 01/2011
3	Cocaine (Cocaine HCl)IBA 07/2014 - 06/2009
3	5-HT1A Serotonin ReceptorIBA 06/2011 - 12/2006
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 09/2005 - 11/2003
3	N-Methylaspartate (NMDA)IBA 09/2005 - 11/2003
3	NNC 112IBA 10/2003 - 05/2002
2	Therapeutic UsesIBA 01/2022 - 01/2007
2	naxagolideIBA 01/2021 - 10/2018
2	Dynorphins (Dynorphin)IBA 01/2021 - 10/2019
2	Naltrexone (ReVia)FDA LinkGeneric 10/2020 - 10/2019
2	Naloxone (Narcan)FDA LinkGeneric 10/2020 - 10/2019
2	Narcotic Antagonists (Opioid Antagonists)IBA 10/2020 - 10/2019
2	Dopamine D3 ReceptorsIBA 02/2020 - 10/2016
2	Dopamine Agonists (Dopamine Agonist)IBA 01/2020 - 01/2015
2	Antidepressive Agents (Antidepressants)IBA 01/2020 - 10/2018
2	Biomarkers (Surrogate Marker)IBA 11/2016 - 10/2016
2	SCH 23390IBA 07/2013 - 09/2003
2	5-HT2A Serotonin Receptor (5 HT2A Receptor)IBA 12/2011 - 11/2011
2	volinanserinIBA 12/2011 - 11/2011
2	N- (2- (4- (2- methoxyphenyl)- 1- piperazinyl)ethyl)- N- (2- pyridinyl)cyclohexanecarboxamideIBA 06/2011 - 12/2006
2	Biological ProductsIBA 10/2010 - 11/2003
2	fallyprideIBA 10/2010 - 12/2008
2	Neurotransmitter Agents (Neurotransmitter)IBA 10/2010 - 01/2010
2	McN 5652IBA 12/2003 - 12/2002
1	SEP-363856IBA 01/2022
1	Serotonin 5-HT2 Receptor AgonistsIBA 01/2022
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2022
1	Trace Amine-Associated ReceptorsIBA 01/2022
1	pimavanserinIBA 01/2022
1	xanomelineIBA 01/2022
1	Dihydroxyphenylalanine (Dopa)IBA 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	Methylphenidate (Ritalin)FDA LinkGeneric 01/2021
1	neuromelaninIBA 11/2020
1	Buprenorphine (Subutex)FDA LinkGeneric 10/2020
1	Opioid Analgesics (Opioids)IBA 10/2020
1	nalmefene (Revex)FDA Link 10/2020
1	dopamine D3 receptor antagonist F17464IBA 02/2020
1	brexpiprazoleIBA 01/2020
1	Levodopa (L Dopa)FDA LinkGeneric 01/2020
1	kappa Opioid Receptors (kappa Opioid Receptor)IBA 10/2019
1	Glutathione (Reduced Glutathione)IBA 01/2019
1	Acetylcysteine (Siran)FDA LinkGeneric 01/2019
1	Pramipexole (Mirapex)FDA LinkGeneric 10/2018
1	RacloprideIBA 01/2018
1	N 30IBA 10/2016
1	cariprazineIBA 10/2016
1	LigandsIBA 10/2016
1	Risperidone (Risperdal Consta)FDA LinkGeneric 10/2015
1	CarbonIBA 04/2015
1	Saline SolutionIBA 01/2015
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2015
1	Glutamine (L-Glutamine)FDA Link 05/2012
1	Aminobutyrates (Aminobutyric Acid)IBA 05/2012
1	ParvalbuminsIBA 05/2012
1	ziprasidone (Geodon)FDA Link 06/2011
1	alpha-Methyltyrosine (Metirosine)FDA Link 06/2009
1	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 01/2009
1	Aripiprazole (Abilify)FDA Link 12/2008
1	Serotonin AgentsIBA 01/2007
1	Serotonin Receptor Agonists (Serotonin Receptor Agonist)IBA 01/2007
1	Nicotine FDA Link 12/2006

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2021